FDA removes diversity trial guidance

Clinical-trial diversity sounds like culture-war shorthand, but the actual issue is basic drug regulation. If the people in a study don’t look enough like the people who will use the drug, the evidence can get thinner exactly where it matters. That is why Congress told the FDA to require diversity action plans for many late-stage drug and device studies. Then, in January 2025, the FDA removed its main draft playbook for those plans from its website just as the new administration was moving against DEI language across government. (federalregister.gov) ### What was this guidance, exactly? The document was a June 2024 draft called “Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies.” It laid out what sponsors should include in a plan — enrollment goals by demographic group, the ra(federalregister.gov)erational map sponsors had. (federalregister.gov) ### Why did sponsors care if it was only draft? Because the legal requirement did not come from the draft. It came from FDORA, the 2022 law that added diversity action plan requirements for certain clinical studies involving drugs and devices. The draft was the instruction manual for complying with that law. So when the webpage disappeared, the statute was still there, but the practical “how do we do this?” layer suddenly got fuzzier. (federalregister.gov) ### What changed in January 2025? Within days of President Trump’s new executive orders aimed at DEI programs and federal references to gender identity, FDA pages tied to diversity in clinical trials started disappearing. Trade press, legal alerts, and policy trackers all flagged the same thing(federalregister.gov) part. If a guidance is being reconsidered, companies usually want to know whether the substance changed, the language changed, or the whole policy changed. (crowell.com) ### Did the requirement itself go away? No — not based on the law. FDORA still required the FDA to issue or update guidance on diversity action plans, and the obligation for sponsors would apply to certain studies beginning 180 days after final guidance is published. The catch is that, as of the material available here, final guidance had not yet been issued. So sponsors were left in a holding pattern — legal mandate in place, final implementation details still unsettled. (federalregister.gov) ### Why is diversity in trials a regulatory issue, not just a political one? Because biology and treatment response are not evenly distributed. Age, sex, race, ethnicity, comorbidities, and access patterns can all shape safety signals and efficacy. A trial that overrepresents one group can miss side effects or dosage issues in another. Basically, this is less like a branding exercise and more like stress-testing a bridge with only half the expected traffic patterns. (statnews.com) ### Was the guidance ever restored? At least some of the removed FDA material came back after court intervention. On February 11, 2025, Judge John Bates ordered FDA, HHS, and CDC to restore webpages removed in the broader purge, and reports the next day said the pages had been restored. That did not erase the policy shock. It just showed that website availability itself had become unstable. (aha.org) ### So what should companies take from this? Treat policy text as movable, but treat traceability as fixed. Sponsors still need defensible cohort definitions, documented enrollment targets, version history, and a clean audit trail showing why a plan looked the way it did at a given time. If the government’s wording shifts, the sponsor that can reconstruct every assumption will be in a much better position than the sponsor that cannot. (regulations.gov) ### Bottom line The FDA website takedown did not erase the underlying law. But it did expose something important — in clinical-trial regulation, uncertainty is not just about science. It is also about whether the rulebook stays in view long enough for people to follow it.